Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (244)	3/3/2000 6:21:00 PM
From: thebeach	Respond to of 356

FOR: PROCYON BIOPHARMA INC. CDNX SYMBOL: PBP MARCH 3, 2000 Procyon Biopharma Announces Proposed Private Placement MONTREAL, QUEBEC--Procyon BioPharma Inc. ("Procyon") announced today that it has engaged Research Capital Corporation ("Research Capital") with a view toward raising capital from a proposed private placement of Special Warrants. Proceeds form the placement will be used to fund research and development of Procyon's products and for general working capital. The terms of such financing are still under discussion and are subject to further agreement. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX under the ticker symbol, PBP. The CDNX has neither approved nor disapproved the information contained in this release.